We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

115 hedge funds and large institutions have $143M invested in Provention Bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more call options, than puts

Call options by funds: $3.51M | Put options by funds: $2.22M

25% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 32

8% less funds holding

Funds holding: 125 → 115 (-10)

27% less capital invested

Capital invested by funds: $197M → $143M (-$53.6M)

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

Holders
115
Holders Change
-10
Holders Change %
-8%
% of All Funds
2.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
40
Reduced
32
Closed
25
Calls
$3.51M
Puts
$2.22M
Net Calls
+$1.29M
Net Calls Change
-$613K

Top Buyers

Rank Fund Capital Flow
1
SC
Sessa Capital
New York
+$9.05M
2
Verition Fund Management
Verition Fund Management
Connecticut
+$4.51M
3
DCM
DG Capital Management
New York
+$3.5M
4
Millennium Management
Millennium Management
New York
+$1.41M
5
N
Nuveen
North Carolina
+$1.35M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$24.5M
2
GGHC
Gilder Gagnon Howe & Co
New York
-$2.43M
3
Charles Schwab
Charles Schwab
California
-$1.52M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.43M
5
First Trust Advisors
First Trust Advisors
Illinois
-$1.15M
Name Holding Trade Value Shares
Change 		Change in
Stake
FWM
126
Frontier Wealth Management
Missouri
– -$223K -26,500 Closed
PAG
127
Private Advisor Group
New Jersey
– -$206K -24,400 Closed
Belvedere Trading
128
Belvedere Trading
Illinois
– -$131K -20,251 Closed
Squarepoint
129
Squarepoint
New York
– -$157K -18,616 Closed
DTL
130
Dynamic Technology Lab
Singapore
– -$128K -15,151 Closed
BAAM
131
Baker Avenue Asset Management
California
– -$120K -14,250 Closed
Two Sigma Advisers
132
Two Sigma Advisers
New York
– -$109K -12,900 Closed
BC
133
Bridgefront Capital
Texas
– -$107K -12,725 Closed
PCM
134
Prelude Capital Management
New York
– -$95K -11,300 Closed
T. Rowe Price Associates
135
T. Rowe Price Associates
Maryland
– -$85K -10,063 Closed
Nisa Investment Advisors
136
Nisa Investment Advisors
Missouri
– -$43 -5,100 Closed
Bank Julius Baer & Co
137
Bank Julius Baer & Co
Switzerland
– -$11K -1,305 Closed
RFA
138
Reilly Financial Advisors
California
– -$2K -200 Closed
Parallax Volatility Advisers
139
Parallax Volatility Advisers
California
– -$1K -132 Closed
2 3 4 5
6

PRVB Hedge Fund Activity: Q3 2021 in Review

115 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2021, worth a combined $143M — down 27% from $197M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of PRVB and 15 opened new positions — a net loss of 10 holders — while 32 trimmed existing stakes and 40 added.

The largest buyer was Sessa Capital, adding an estimated $9.05M. The largest seller was VR Adviser, exiting entirely with an estimated $24.5M sold.

  • 115 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2021, down from 125 in Q2 2021.
  • Funds reported $143M of Provention Bio, Inc. Common Stock stock for Q3 2021, down 27% quarter-over-quarter.
  • 15 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2021 and 25 closed out, a net change of -10 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q3 2021 was Sessa Capital, an estimated $9.05M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q3 2021 was VR Adviser, an estimated $24.5M sold.

Based on aggregated 13F filings for Q3 2021.